Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 16/20 | 0.49 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23320499 | 0.92 | NAMPT (0.47) | NAMPTIMPDH2HTTROCK2ROCK1 | |
| SCHEMBL23320463 | 0.84 | PRMT3 (0.45) | NAMPTROCK2ROCK1RAB9A | |
| SCHEMBL23320481 | 0.81 | NAMPT (0.57) | NAMPTIMPDH2HTTROCK2ROCK1 | |
| SCHEMBL30943269 | 0.78 | NAMPT (0.54) | NAMPTIMPDH2HTTROCK2ROCK1 | |
| SCHEMBL24042574 | 0.78 | NAMPT (0.54) | NAMPTIMPDH2HTTROCK2ROCK1 | |
| SCHEMBL23320504 | 0.78 | NAMPT (0.54) | NAMPTIMPDH2HTTROCK2ROCK1 | |
| SCHEMBL23320580 | 0.78 | NAMPT (0.59) | NAMPTIMPDH2HTTROCK2ROCK1 | |
| SCHEMBL30943163 | 0.78 | NAMPT (0.59) | NAMPTIMPDH2HTTROCK2ROCK1 | |
| SCHEMBL23320503 | 0.74 | NAMPT (0.55) | NAMPTIMPDH2HTTROCK2ROCK1 | |
| SCHEMBL23320514 | 0.74 | NAMPT (0.55) | NAMPTIMPDH2HTTROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3818053-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-05-12 | — | — | EP | claimed |
| CN-112654608-B | Fused ring compound having urea structure | 桑福德伯纳姆普利斯医学发现研究所 | 2024-05-07 | — | — | CN | disclosed |
| US-20210361636-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2021-11-25 | — | — | US | disclosed |
| EP-3818053-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361636-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | NAMPT, NME4, ABAT | NAMPT 1/4885IMPDH2 352/4885HTT 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.